Pfizer Independent Medical Education Grant Request for Proposals: New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer Inc. funds education projects advancing knowledge of new mechanisms and emerging treatments, especially EZH2 inhibition, in metastatic castration resistant prostate cancer (mCRPC).
Browse similar grants
Funder: Pfizer Inc.
Due Dates: October 21, 2026 (Submission Deadline)
Funding Amounts: $75,000–$250,000 per project | Up to 18–24 months duration | Total program budget: $750,000
Summary: Supports independent medical education projects that advance understanding of new mechanisms and emerging treatments—especially EZH2 inhibition—for metastatic castration resistant prostate cancer (mCRPC).
Key Information: Only organizations (not individuals) may apply; clinical research projects are not eligible.
Description
Pfizer Inc. is offering a competitive grant program to support independent medical education initiatives focused on new mechanisms and emerging treatment options in metastatic castration resistant prostate cancer (mCRPC). The emphasis is on educational activities that enhance healthcare professionals’ understanding of differentiated mechanisms of action, particularly EZH2 inhibition and its role in prostate cancer, as well as the need for novel therapies beyond chemotherapy. Supported projects should address knowledge gaps in the field, such as the role of EZH2 and other novel mechanisms in prostate cancer progression, investigational approaches combining EZH2 and AR inhibition, and updates on ongoing clinical trials relevant to mCRPC. Eligible educational formats include live conference sessions, symposia, online content, and multimedia materials.
